Myriad Genetics (NASDAQ:MYGN) CEO Samraat S. Raha disclosed an insider purchase of 40,000 common shares executed on March 9, 2026. The total outlay for the acquisition was $199,844, with individual share prices in the range of $4.97 to $5.00, figures that are close to the prevailing market quote of $4.81.
Following this transaction, Raha's direct ownership of Myriad stock stands at 493,104 shares. The purchase comes against a backdrop of a sizable one-year decline in the company's equity value - a drop of 52.75% over the last 12 months.
Operationally, Myriad reported fourth-quarter 2025 results that beat analyst estimates on an adjusted basis. The company delivered adjusted earnings per share of $0.04, compared with a forecasted loss of $0.02. Revenue for the quarter was $209.8 million, topping the anticipated $207.17 million. These results represent a performance above market expectations for the quarter in question.
Despite the recent quarterly upside, the company was not profitable over the preceding twelve-month period. InvestingPro Tips referenced in the reporting indicate that analysts expect Myriad to achieve profitability in the current year.
The insider purchase and the quarterly results are highlighted alongside other personnel movement in the life sciences sector noted in the reporting. Diality Inc. named Peter Donato as its new chief financial officer; Donato's background includes nearly 35 years in financial leadership and prior roles as CFO at Impulse Dynamics and Zomedica. The announcement frames Donato's hire as a reinforcement of Diality's financial leadership.
Context and implications
The CEO's purchase represents a direct ownership increase and signals a personal capital commitment at price points near current trading levels. At the same time, the company's mixed picture - a quarterly beat but a year-long unprofitable stretch and a steep share-price decline - creates a nuanced backdrop for investors and analysts tracking the name.
Investors seeking more detailed, model-driven analysis may refer to the InvestingPro Pro Research coverage mentioned in the reporting, which includes a broader set of US equity reports and financial metrics. That coverage is cited as offering additional perspective on valuation and the path to profitability.
Summary of facts
- CEO Samraat S. Raha bought 40,000 shares on March 9, 2026, for a total of $199,844 at $4.97 to $5.00 per share.
- Raha now directly owns 493,104 shares of Myriad Genetics.
- Myriad reported adjusted Q4 2025 EPS of $0.04 versus an expected loss of $0.02, and revenue of $209.8 million versus $207.17 million expected.
- The stock has fallen 52.75% over the past year and the company was not profitable over the last twelve months; analysts cited expect profitability this year.